Literature DB >> 29885519

Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.

Guo-Hao Huang1, Lei Du1, Ningning Li2, Ying Zhang3, Yan Xiang1, Jun-Hai Tang1, Shuli Xia4, Eric Erquan Zhang5, Sheng-Qing Lv6.   

Abstract

Gliomas with isocitrate dehydrogenases gene mutations (IDHMT) were found to be less aggressive than their wildtype (IDHWT) counterparts. However, the mechanism remains unclear. The current study aims to investigate the role of silenced oncogenic microRNAs in IDHMT gliomas, which were largely ignored and may contribute to the less aggressive behavior of IDHMT gliomas. Microarrays, bioinformatics analysis of the data from TCGA and qPCR analysis of samples from our experimental cohort (LGG: IDHWT = 10, IDHMT = 31; GBM: IDHWT = 34, IDHMT = 9) were performed. The results show that miR-155 was consistently down-regulated in IDHMT gliomas. Establishment of IDH1R132H overexpressing glioma cell line and bisulfite sequencing PCR suggested that miR-155 down-regulation was associated with IDH1R132H mutation induced promoter CpG islands methylation. The cancer testis antigen FAM133A is a direct downstream target of miR-155 and is a negative regulator of glioma invasion and migration possibly by regulating matrix metallopeptidase 14 (MMP14). Together, we found that methylation-regulated miR-155-FAM133A axis may contribute to the attenuated invasion and migration of IDHMT gliomas by targeting MMP14.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioma; IDH mutation; Methylation; Migration and invasion; miR-155

Mesh:

Substances:

Year:  2018        PMID: 29885519     DOI: 10.1016/j.canlet.2018.06.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  8 in total

1.  A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.

Authors:  Wei Wu; Yichang Wang; Jianyang Xiang; Xiaodong Li; Alafate Wahafu; Xiao Yu; Xiaobin Bai; Ge Yan; Chunbao Wang; Ning Wang; Changwang Du; Wanfu Xie; Maode Wang; Jia Wang
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Low Expression of APOB mRNA or Its Hypermethylation Predicts Favorable Overall Survival in Patients with Low-Grade Glioma.

Authors:  Chong Han; Yang He; Lifen Chen; Jie Wang; Song Jiao; Xiangping Xia; Gang Li; Shengtao Yao
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

3.  Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.

Authors:  Chubei Teng; Yongwei Zhu; Yueshuo Li; Luohuan Dai; Zhouyang Pan; Siyi Wanggou; Xuejun Li
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

4.  Multi-Omics Data Analyses Construct a Six Immune-Related Genes Prognostic Model for Cervical Cancer in Tumor Microenvironment.

Authors:  Fangfang Xu; Jiacheng Shen; Shaohua Xu
Journal:  Front Genet       Date:  2021-05-24       Impact factor: 4.599

5.  Methylation of HIF3A promoter CpG islands contributes to insulin resistance in gestational diabetes mellitus.

Authors:  Yinghong Zhang; Yangyang Chen; Hongmei Qu; Yuanli Wang
Journal:  Mol Genet Genomic Med       Date:  2019-02-11       Impact factor: 2.183

6.  Identification and Potential Mechanisms of a 7-MicroRNA Signature That Predicts Prognosis in Patients with Lower-Grade Glioma.

Authors:  Zhizheng Liu; Hongliang Meng; Miaoxian Fang; Wenlong Guo
Journal:  J Healthc Eng       Date:  2021-11-20       Impact factor: 2.682

7.  Integrated Analysis of a Risk Score System Predicting Prognosis and a ceRNA Network for Differentially Expressed lncRNAs in Multiple Myeloma.

Authors:  Sijie Zhou; Jiuyuan Fang; Yan Sun; Huixiang Li
Journal:  Front Genet       Date:  2020-08-27       Impact factor: 4.599

8.  MicroRNA‑4712‑5p promotes proliferation of the vulvar squamous cell carcinoma cell line A431 by targeting PTEN through the AKT/cyclin D1 signaling pathways.

Authors:  Shaojie Yang; Yanyan Zhao; Lufang Wang; Chang Liu; Ye Lu; Zhidong Fang; Hongshuang Shi; Wenyi Zhang; Xin Wu
Journal:  Oncol Rep       Date:  2019-09-17       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.